AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

Optec International, Inc.

$0 +$0.00 (+30.77%)
OTC · 14 Sep 2026 20:00 UTC
Previous Close
$0
Day Range
$0$0
Year Range
$0$0
Market Cap
2.91M
AVG Volume
1.79M
Trailing/Forward PE
-4.25/-
PEG ratio
-0.04
Dividend Yield
-
Next Earnings Date
-
Primary Exchange
Other OTCUS
Revenue (USD)
-500K0500K1M1.5M2M17 Q418 Q118 Q218 Q318 Q419 Q119 Q221 Q422 Q122 Q2
OPTI Revenue (USD) by quarter
PeriodRevenue (USD)
22 Q21.55M
22 Q129.1K
21 Q41M
19 Q20
19 Q115.25K
18 Q40
18 Q3305
18 Q2-3.85K
18 Q194.65K
17 Q40
Net Income (USD)
-3M-2M-1M01M17 Q418 Q118 Q218 Q318 Q419 Q119 Q221 Q422 Q122 Q2
OPTI Net Income (USD) by quarter
PeriodNet Income (USD)
22 Q2-241.21K
22 Q1-814.42K
21 Q4385.04K
19 Q2-2.95M
19 Q1-1.16M
18 Q4-518.02K
18 Q3-440.09K
18 Q2-388.3K
18 Q125.54K
17 Q4-10.05K
Operating Income (USD)
-1M-500K0500K1M17 Q418 Q118 Q218 Q318 Q419 Q119 Q221 Q422 Q122 Q2
OPTI Operating Income (USD) by quarter
PeriodOperating Income (USD)
22 Q2-116.31K
22 Q1-687.32K
21 Q4516.71K
19 Q2-62.91K
19 Q1-65.48K
18 Q4-83.06K
18 Q3-23.89K
18 Q2-90.17K
18 Q125.54K
17 Q4-10.05K
EBITDA (USD)
-1M-500K0500K1M17 Q418 Q118 Q218 Q318 Q419 Q119 Q221 Q422 Q122 Q2
OPTI EBITDA (USD) by quarter
PeriodEBITDA (USD)
22 Q2-3.75K
22 Q1-574.75K
21 Q4631.89K
19 Q2-242.64K
19 Q1-550.41K
18 Q46.56K
18 Q3-927.17K
18 Q2-50.08K
18 Q1-52.65K
17 Q4-78.54K
Cash Flows (USD)
-2M-1M01M17 Q418 Q118 Q218 Q318 Q419 Q119 Q221 Q422 Q122 Q2
OPTI Cash Flows (USD) by quarter
PeriodCash Flows (USD)
22 Q2931.87K
22 Q1-1.15M
21 Q4-129.35K
19 Q2-157.64K
19 Q1-57.72K
18 Q4-159.08K
18 Q391.2K
18 Q2-216.23K
18 Q12.29K
17 Q4-1.63K
EPS (USD)
-0.2-0.15-0.1-0.05-00.0517 Q418 Q118 Q218 Q318 Q419 Q119 Q221 Q422 Q122 Q2
OPTI EPS (USD) by quarter
PeriodEPS (USD)
22 Q2-0
22 Q1-0
21 Q40
19 Q2-0.17
19 Q1-0.07
18 Q40
18 Q3-0.02
18 Q2-0.01
18 Q10
17 Q4-0.01
Expenses (USD)
-3M-2M-1M01MSG&ACapex17 Q418 Q118 Q218 Q318 Q419 Q119 Q221 Q422 Q122 Q2
OPTI Expenses (USD) by quarter
PeriodExpenses (USD)
22 Q2-547.46K
22 Q1-1.45M
21 Q4380.21K
19 Q252.48K
19 Q163.5K
18 Q428.96K
18 Q323.22K
18 Q249.74K
18 Q19.73K
17 Q49.04K
Cash & Debt (USD)
05M10M15MCashShort Term Debt17 Q418 Q118 Q218 Q318 Q419 Q119 Q221 Q422 Q122 Q2
OPTI Cash & Debt (USD) by quarter
PeriodCash & Debt (USD)
22 Q2505
22 Q14.25K
21 Q4412.39K
19 Q29.24K
19 Q131.27K
18 Q430.8K
18 Q3711
18 Q22.01K
18 Q12.63K
17 Q4342
Debt ratios
-100-75-50-2502517 Q418 Q118 Q218 Q318 Q419 Q119 Q221 Q422 Q122 Q2
OPTI Debt ratios by quarter
PeriodDebt ratios
22 Q2-79.14
22 Q1-20.18
21 Q4-92.52
19 Q2-0.5
19 Q1-0.29
18 Q4-0.4
18 Q3-0.11
18 Q2-0.2
18 Q10.01
17 Q40
Margins
-300%-200%-100%0%100%17 Q117 Q217 Q318 Q118 Q218 Q319 Q121 Q422 Q122 Q2
OPTI Margins by quarter
PeriodMargins
22 Q2-7.24%
22 Q1-286.81%
21 Q488.51%
19 Q171.14%
18 Q3100%
18 Q2100%
18 Q138.34%
17 Q341.67%
17 Q2100%
17 Q1100%
Return on Capital
-100%0%100%200%17 Q418 Q118 Q218 Q318 Q419 Q119 Q221 Q422 Q122 Q2
OPTI Return on Capital by quarter
PeriodReturn on Capital
22 Q2-18.48%
22 Q1-52.66%
21 Q418.41%
19 Q266.09%
19 Q150.46%
18 Q445.33%
18 Q356.7%
18 Q2115.54%
18 Q170.5%
17 Q4-94.04%
Shares Outstanding
01B2B3B4B17 Q418 Q118 Q218 Q318 Q419 Q119 Q221 Q422 Q122 Q2
OPTI Shares Outstanding by quarter
PeriodShares Outstanding
22 Q23.73B
22 Q12.95B
21 Q42.87B
19 Q217.86M
19 Q117.83M
18 Q40
18 Q319.25M
18 Q238.24M
18 Q152.94M
17 Q452.94M
Book Value Per Share (USD)
-0.3-0.2-0.1-00.117 Q317 Q418 Q118 Q218 Q319 Q119 Q221 Q422 Q122 Q2
OPTI Book Value Per Share (USD) by quarter
PeriodBook Value Per Share (USD)
22 Q20
22 Q10
21 Q40
19 Q2-0.25
19 Q1-0.13
18 Q3-0.04
18 Q2-0.01
18 Q10
17 Q40
17 Q30
Total Assets (USD)
05M10M15M20M17 Q418 Q118 Q218 Q318 Q419 Q119 Q221 Q422 Q122 Q2
OPTI Total Assets (USD) by quarter
PeriodTotal Assets (USD)
22 Q217.32M
22 Q117.43M
21 Q418.3M
19 Q21.08M
19 Q1840.23K
18 Q4626.37K
18 Q3237.38K
18 Q2239.85K
18 Q1105.16K
17 Q417.69K
Employee Count
00.511.522018
OPTI Employee Count by quarter
PeriodEmployee Count
20181
PE Ratio
13500140001450015000med 14002.94Jan 18Jan 18Feb 18Feb 18Mar 18Mar 18Mar 18
OPTI PE Ratio by quarter
PeriodPE Ratio
Mar 1813652.53
Mar 1813652.53
Mar 1813652.53
Mar 1813622.19
Mar 1814201.66
Feb 1814201.66
Feb 1814201.66
Feb 1814201.66
Feb 1813652.53
Jan 1813652.53
Jan 1814259.31
Jan 1814259.31
Jan 1814691.64
Dec 1713804.22
Free Cash Flow Yield
-80%-60%-40%-20%0%med -8.53%Dec 24Apr 25Jul 25Nov 25Feb 26Jun 26Sep 26
OPTI Free Cash Flow Yield by quarter
PeriodFree Cash Flow Yield
Sep 26-8.03%
Sep 26-8.03%
Sep 26-7.58%
Aug 26-7.58%
Aug 26-6.82%
Aug 26-6.82%
Aug 26-6.2%
Jul 26-7.58%
Jul 26-13.64%
Jul 26-10.49%
Jul 26-17.05%
Jul 26-19.49%
Jun 26-34.11%
Jun 26-45.48%
Jun 26-45.48%
Jun 26-34.11%
May 26-45.48%
May 26-34.11%
May 26-34.11%
May 26-27.29%
May 26-34.11%
Apr 26-34.11%
Apr 26-34.11%
Apr 26-34.11%
Apr 26-34.11%
Mar 26-34.11%
Mar 26-13.64%
Mar 26-6.5%
Mar 26-15.16%
Feb 26-15.16%
Feb 26-22.74%
Feb 26-27.29%
Feb 26-68.21%
Jan 26-34.11%
Jan 26-45.48%
Jan 26-10.49%
Jan 26-8.53%
Jan 26-10.49%
Dec 25-7.8%
Dec 25-6.2%
Dec 25-6.82%
Dec 25-8.03%
Nov 25-8.03%
Nov 25-5.93%
Nov 25-5.25%
Nov 25-11.37%
Oct 25-11.37%
Oct 25-8.53%
Oct 25-13.64%
Oct 25-11.37%
Oct 25-9.1%
Sep 25-9.74%
Sep 25-11.37%
Sep 25-12.4%
Sep 25-9.1%
Aug 25-9.1%
Aug 25-8.53%
Aug 25-8.53%
Aug 25-7.58%
Aug 25-10.49%
Jul 25-7.58%
Jul 25-10.49%
Jul 25-9.1%
Jul 25-10.49%
Jun 25-6.82%
Jun 25-8.53%
Jun 25-7.58%
Jun 25-6.82%
May 25-7.18%
May 25-6.2%
May 25-7.58%
May 25-5.46%
May 25-7.58%
Apr 25-5.46%
Apr 25-5.93%
Apr 25-5.25%
Apr 25-6.5%
Mar 25-6.2%
Mar 25-4.87%
Mar 25-6.82%
Mar 25-4.55%
Feb 25-4.55%
Feb 25-4.87%
Feb 25-4.55%
Feb 25-5.93%
Jan 25-9.74%
Jan 25-8.53%
Jan 25-9.41%
Jan 25-8.53%
Jan 25-6.5%
Dec 24-7.58%
Dec 24-10.49%
Dec 24-9.1%
Dec 24-6.82%
Nov 24-6.82%
Nov 24-6.82%
Nov 24-6.82%
Nov 24-6.82%
Nov 24-6.82%
Oct 24-7.18%
Price to Sales
0246med 2.31Dec 24Apr 25Jul 25Nov 25Feb 26Jun 26Sep 26
OPTI Price to Sales by quarter
PeriodPrice to Sales
Sep 262.45
Sep 262.45
Sep 262.59
Aug 262.59
Aug 262.88
Aug 262.88
Aug 263.17
Jul 262.59
Jul 261.44
Jul 261.87
Jul 261.15
Jul 261.01
Jun 260.58
Jun 260.43
Jun 260.43
Jun 260.58
May 260.43
May 260.58
May 260.58
May 260.72
May 260.58
Apr 260.58
Apr 260.58
Apr 260.58
Apr 260.58
Mar 260.58
Mar 261.44
Mar 263.03
Mar 261.3
Feb 261.3
Feb 260.86
Feb 260.72
Feb 260.29
Jan 260.58
Jan 260.43
Jan 261.87
Jan 262.31
Jan 261.87
Dec 252.52
Dec 253.17
Dec 252.88
Dec 252.45
Nov 252.45
Nov 253.31
Nov 253.75
Nov 251.73
Oct 251.73
Oct 252.31
Oct 251.44
Oct 251.73
Oct 252.16
Sep 252.02
Sep 251.73
Sep 251.59
Sep 252.16
Aug 252.16
Aug 252.31
Aug 252.31
Aug 252.59
Aug 251.87
Jul 252.59
Jul 251.87
Jul 252.16
Jul 251.87
Jun 252.88
Jun 252.31
Jun 252.59
Jun 252.88
May 252.74
May 253.17
May 252.59
May 253.6
May 252.59
Apr 253.6
Apr 253.31
Apr 253.75
Apr 253.03
Mar 253.17
Mar 254.03
Mar 252.88
Mar 254.32
Feb 254.32
Feb 254.03
Feb 254.32
Feb 253.31
Jan 252.02
Jan 252.31
Jan 252.09
Jan 252.31
Jan 253.03
Dec 242.59
Dec 241.87
Dec 242.16
Dec 242.88
Nov 242.88
Nov 242.88
Nov 242.88
Nov 242.88
Nov 242.88
Oct 242.74
EV/EBITDA
02500500075001000012500med 11067.35Dec 16Jan 17Jan 17Feb 17Feb 17Mar 17Mar 17
OPTI EV/EBITDA by quarter
PeriodEV/EBITDA
Mar 172459.28
Mar 172459.28
Mar 172459.28
Mar 172459.28
Feb 172459.28
Feb 1711067.35
Feb 1711067.35
Feb 1711067.35
Jan 1711067.35
Jan 1711067.35
Jan 1711067.35
Jan 1711067.35
Dec 1611067.35
Price to Book
0246810med 4.57Dec 24Apr 25Jul 25Nov 25Feb 26Jun 26Sep 26
OPTI Price to Book by quarter
PeriodPrice to Book
Sep 264.85
Sep 264.85
Sep 265.14
Aug 265.14
Aug 265.71
Aug 265.71
Aug 266.28
Jul 265.14
Jul 262.85
Jul 263.71
Jul 262.28
Jul 262
Jun 261.14
Jun 260.86
Jun 260.86
Jun 261.14
May 260.86
May 261.14
May 261.14
May 261.43
May 261.14
Apr 261.14
Apr 261.14
Apr 261.14
Apr 261.14
Mar 261.14
Mar 262.85
Mar 265.99
Mar 262.57
Feb 262.57
Feb 261.71
Feb 261.43
Feb 260.57
Jan 261.14
Jan 260.86
Jan 263.71
Jan 264.57
Jan 263.71
Dec 254.99
Dec 256.28
Dec 255.71
Dec 254.85
Nov 254.85
Nov 256.56
Nov 257.42
Nov 253.42
Oct 253.42
Oct 254.57
Oct 252.85
Oct 253.42
Oct 254.28
Sep 254
Sep 253.42
Sep 253.14
Sep 254.28
Aug 254.28
Aug 254.57
Aug 254.57
Aug 255.14
Aug 253.71
Jul 255.14
Jul 253.71
Jul 254.28
Jul 253.71
Jun 255.71
Jun 254.57
Jun 255.14
Jun 255.71
May 255.42
May 256.28
May 255.14
May 257.14
May 255.14
Apr 257.14
Apr 256.56
Apr 257.42
Apr 255.99
Mar 256.28
Mar 257.99
Mar 255.71
Mar 258.56
Feb 258.56
Feb 257.99
Feb 258.56
Feb 256.56
Jan 254
Jan 254.57
Jan 254.14
Jan 254.57
Jan 255.99
Dec 245.14
Dec 243.71
Dec 244.28
Dec 245.71
Nov 245.71
Nov 245.71
Nov 245.71
Nov 245.71
Nov 245.71
Oct 245.42
Optec International, Inc.
OPTI
Stockpicker

Video analysis: OPTI

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: OPTI

Optimi Health Establishes Discretionary Equity Facility

globenewswire.com · 14 Aug 2026

Optimi Health Establishes Discretionary Equity Facility

VANCOUVER, British Columbia, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) (the “Company” or “Optimi”), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced that it has entered into a common shares purchase agreement (the “Purchase Agreement”) with Seven Knots, LLC (“Seven Knots”), establishing an equity line of credit (the “ELOC”) under which the Company has the right, but not the obligation, to sell to Seven Knots up to US$100 million of its common shares from time to time over the term of the facility.

Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research

globenewswire.com · 16 Jun 2026

Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research

Two naturally derived finished drug products, at 1mg and 2mg, give research organizations the consistent, validated doses required for controlled studies New microdose formats extend Optimi's psilocybin range, which includes a 5mg formulation currently commercially prescribed for treatment-resistant depression in Australia under the country's Authorized Prescriber Scheme VANCOUVER, British Columbia, June 16, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "Company" or "Optimi"), a commercial-stage GMP pharmaceutical manufacturer of regulated psychedelic drug products, today announced it has completed production of two microdose psilocybin finished drug products, formulated at 1 mg and 2 mg dosages. The products are available to qualified, authorized clinical research organizations.

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.